Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
AverageWe are a global biopharmaceutical company dedicated to the discovery, development and commercialization of clinically differentiated medicines for children and adults living with rare disorders. We are advancing a robust and diversified pipeline of transformative medicines as part of our mission to provide access to best-in-class treatments for patients with unmet medical needs. Our strategy is to leverage our scientific expertise and global commercial infrastructure to optimize value for our patients and other stakeholders.
In the company’s own words · 10-K filed Feb 19, 2026 · SEC EDGAR
Business segments
Q2 2026 · $336.8MThe company’s own SEC segment disclosure.
- Sephience$127.5M38%
- Royalty$71.1M21%
- Collaboration And License$50.6M15%
- Translarna$42.2M13%
- Emflaza$24.6M7%
- Upstaza And Kebilidi$11.2M3%
- Other (1)$9.5M3%
PTC Therapeutics, Inc. (PTCT) reported revenue of $361M in Q2 2026 (quarter ended Jun 30, 2026), up 102% from the same quarter a year earlier. That came with net income of $83M (23% of revenue). For the full year FY2025, revenue was $1.73B (+115% year on year) and net income $683M. Its largest product in Q2 2026 was Sephience at $128M, 38% of the disclosed total, ahead of Royalty at 21%.
Raw charts
11 series · TTMAs reported to the SEC, without any scoring.